ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 056

Non-criteria Antiphospholipid Antibodies Associated with Pediatric Rheumatic Disease: A Single-Center Case Series

Shawn Mahmud1, Danielle Bullock 1, Colleen Correll 1, Patricia Hobday 2, Mona Riskalla 3, Richard Vehe 4 and Bryce Binstadt 1, 1University of Minnesota, Minneapolis, 2Minneapolis, 3University of Minnesota, Minneapolis, Minnesota, 4University of Minnesota, Roseville

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: Mixed connective tissue disease (MCTD), non-criteria antiphospholipid antibodies, seronegative antiphospholipid syndrome, Sjogren's syndrome, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Thursday, April 30, 2020

Title: Poster Session 1

Session Type: ACR Abstract Session

Session Time: 6:00PM-7:00PM

Background/Purpose: Non-criteria antiphospholipid antibodies (NC-aPL) bind molecules such as phosphatidylethanolamine (PE), phosphatidylserine (PS), and prothrombin (Pt), but not the targets of routine antiphospholipid (aPL) testing (i.e., cardiolipin and beta 2 glycoprotein 1). In adults, the term “seronegative” antiphospholipid syndrome (APS) refers to patients with a history of thrombosis with negative conventional aPL testing, but with a positive lupus anticoagulant (LAC) and/or positive NC-aPL. The clinical significance of NC-aPL remains poorly characterized particularly in pediatric patients. The aims of this study were to review the clinical presentation, diagnostic evaluation, and response to therapy in pediatric patients with NC-aPL.

Methods: A retrospective chart review was conducted on 5 pediatric patients with positive NC-aPL at a single center. All data from the initial encounter with pediatric rheumatology until January 2020 were reviewed, ranging from 12-45 months.

Results: Data are summarized in Table 1. All 5 patients were females, aged 7-16 years. Presenting symptoms and signs varied, but all had neurologic and/or skin manifestations. Patient 1 had brain MRI evidence of an acute cerebellar stroke, basal ganglia white matter changes, and mitral valve abnormalities. Patients 2-4 presented with Raynaud’s phenomenon and various symptoms from underlying autoimmune disorders but had no evidence of thrombosis. Patient 5 presented with superficial vasculitic skin lesions and Raynaud’s phenomenon. All 5 patients were treated with hydroxychloroquine (HCQ). Anti-platelet drugs were used in patients deemed most at risk for thrombosis. Patient 1 had evolving brain MRI abnormalities while weaning corticosteroids (CS), and therefore rituximab (RTX) was added. Patient 2, who had SLE with nephritis, was treated with CS, mycophenolate mofetil (MMF), and RTX. In 1 of 2 patients treated with RTX, NC-aPL were no longer detectable even after B cell repopulation. In patient 3, treated with HCQ alone, NC-aPL were also undetectable after 4 months of therapy. Most notably, in patient 1, the chorea resolved and migraine headaches improved after RTX and she has had no further progression of brain MRI changes or mitral valve abnormalities.  

Conclusion: NC-aPL are not routinely tested in pediatric patients presenting with symptoms consistent with APS, even in the presence of a defined rheumatic disease. Among the patients in this series, patient 1 appears to have primary APS, while patients 2-4 have NC-aPL secondary to ANA-associated diseases with no history of thrombosis. Patient 5 had a persistently positive lupus anticoagulant but no evidence of deep vein or arterial thrombosis and thus did not meet criteria for APS. HCQ therapy was well tolerated by all 5 patients. Two patients received RTX, and in one case, resolution of symptoms after RTX coincided with normalization of NC-aPL titers. Prospective data are needed to understand the significance of NC-aPL, but these data suggest clinicians should consider testing NC-aPL in patients with features of APS but negative conventional aPL testing.

Table 1. Characteristics of 5 pediatric patients with NC_aPL. The normal ranges of the indicated tests are indicated in parentheses. Patients 4 and 5 are full siblings, presented similarly, and are suspected to have partial genetic C4 deficiency. Abbreviations: anti_cardiolipin: aCL; anti_beta 2 glycoprotein_1: b2GP1).


Disclosure: S. Mahmud, None; D. Bullock, None; C. Correll, None; P. Hobday, None; M. Riskalla, None; R. Vehe, None; B. Binstadt, None.

To cite this abstract in AMA style:

Mahmud S, Bullock D, Correll C, Hobday P, Riskalla M, Vehe R, Binstadt B. Non-criteria Antiphospholipid Antibodies Associated with Pediatric Rheumatic Disease: A Single-Center Case Series [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/non-criteria-antiphospholipid-antibodies-associated-with-pediatric-rheumatic-disease-a-single-center-case-series/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/non-criteria-antiphospholipid-antibodies-associated-with-pediatric-rheumatic-disease-a-single-center-case-series/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology